GWM
ABBV icon

Gitterman Wealth Management’s AbbVie ABBV Stock Holding History

Gitterman Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-818
Closed -$152K – 129
2025
Q2 		$152K Buy
+818
New +$152K 0.04% 195
2025
Q1 		– Sell
-1,497
Closed -$266K – 132
2024
Q4 		$266K Buy
+1,497
New +$275K 0.11% 83
2024
Q3 		– Sell
-2,719
Closed -$467K – 128
2024
Q2 		$467K Buy
+2,719
New +$450K 0.18% 31

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Gitterman Wealth Management's ABBV Position: Q3 2025 in Review

Gitterman Wealth Management sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 818 shares — an estimated $152K sold.

Gitterman Wealth Management first reported a position in ABBV in Q2 2024 and held it in 3 quarters. The position peaked at $467K in Q2 2024. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Gitterman Wealth Management reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
  • Gitterman Wealth Management sold 818 AbbVie shares in Q3 2025, an estimated $152K.
  • Gitterman Wealth Management first reported a position in AbbVie in Q2 2024 and held it in 3 quarters.
  • Gitterman Wealth Management's AbbVie position peaked at $467K in Q2 2024.
  • 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Gitterman Wealth Management's 13F filing for Q3 2025, filed 4 Nov 2025.